See more : Fluence Corporation Limited (EMFGF) Income Statement Analysis – Financial Results
Complete financial analysis of 89bio, Inc. (ETNB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 89bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Maison Clio Blue SA (MLCLI.PA) Income Statement Analysis – Financial Results
- Switchback II Corporation (SWBK) Income Statement Analysis – Financial Results
- eMemory Technology Inc. (3529.TWO) Income Statement Analysis – Financial Results
- Keros Therapeutics, Inc. (KROS) Income Statement Analysis – Financial Results
- Ouster, Inc. (OUST-WTA) Income Statement Analysis – Financial Results
89bio, Inc. (ETNB)
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| Gross Profit | -273.00K | -240.00K | -79.00K | -60.00K | -17.00K | -6.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 122.23M | 80.80M | 70.33M | 36.20M | 21.35M | 13.68M |
| General & Administrative | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Other Expenses | 0.00 | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Operating Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Cost & Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Interest Income | 0.00 | 2.16M | 148.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.59M | 1.92M | 674.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| EBITDA | -134.46M | -99.85M | -90.19M | -49.50M | -57.19M | -16.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.20M | 102.25M | -89.74M | -49.36M | -26.64M | -15.16M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.88M | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Income Before Tax | -138.32M | -102.01M | -90.27M | -49.56M | -57.20M | -16.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.87M | 19.00K | -147.00K | -59.00K | 218.00K | 28.00K |
| Net Income | -142.19M | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| EPS Diluted | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| Weighted Avg Shares Out | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
| Weighted Avg Shares Out (Dil) | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
The mean of analysts' price targets for 89BIO (ETNB) points to an 80% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
4 Best Breakout Stocks to Buy for Superb Returns
Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89BIO (ETNB) have been selected as the breakout stocks for today.
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data from the...
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
Orbimed Advisors Reduces Position in 89bio
Fintel reports that Orbimed Advisors Llc has filed a 13D/A form with the SEC disclosing ownership of 1.50MM shares of 89bio Inc (ETNB).
89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?
89BIO (ETNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
89Bio: Let's Not Give Up Already
ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action.
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate...
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company's Management will participate...
89bio: NASH Data Next Year May Change Things For The Better
ETNB stock has remained depressed for a long time. Not even solid SHTG data could change that.
Source: https://incomestatements.info
Category: Stock Reports